Tag Archives: LAL-D

November, 2017

December, 2015

  • 8 December

    FDA Approves Alexion’s Kanuma for Patients with a Rare Enzyme Disease

    CHESHIRE, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Kanuma™(sebelipase alfa) for the treatment of patients of all ages with a diagnosis of lysosomal acid lipase deficiency (LAL-D). Kanuma, an innovative enzyme replacement therapy (ERT), is the first therapy approved …